NVP-BGT226 - PI3K/mTOR Dual Inhibitor. CAS# 1245537-68-1 ral-LSB [Epub ahead of print] PubMed

[Epub ahead of print] PubMed PMID: 24365180

It increases H3K4 methylation selectively at genomic regions bound by LSD1

Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma

InChi: InChI=1S/C23H28N2O2

including initiation of protein synthesis

NVP-BGT226 - PI3K/mTOR Dual Inhibitor. CAS# 1245537-68-1 ral-LSB [Epub ahead of print] PubMedNVP BGT226, CAS No. 1245537 68 1, is a novel dual PI3K mTOR inhibitor with an IC50 ~1 nM. In cellular assays it could produce nearly complete inhibition of PI3K signaling at low nanomolar (<50 nM) concentrations. Flow cytometric analysis revealed an accumulation of cells in the G0G1 phase with a concomitant loss in the S phase. TUNEL assay and the analysis of Caspase 3 7 and PARP indicated that BGT226 induced cancer cell death through an apoptosis